GlassScriptPhysician profile
Jayne S Gurtler
NPI 1396712808
$2,782.92
in general payments reported to CMS, 2019-2025
29 companies · $663 in 2025
The $663 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $67.09 · 2021: $275 · 2022: $211 · 2023: $357 · 2024: $856 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.33 |
| Education | $299.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $391.05 | 2022-2025 | |
| Janssen Biotech, INC. | $375.92 | 2019-2025 | Erleada |
| Amgen INC. | $252.31 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $238.72 | 2020-2025 | |
| Astellas Pharma US INC | $218.24 | 2019-2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $135.60 | 2019-2024 | |
| Array Biopharma INC | $116.89 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Abbvie INC. | $114.10 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.87 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.82 | 2022 | |
| Sobi, INC | $99.99 | 2024 | |
| Merck Sharp & Dohme LLC | $95.64 | 2019-2022 | |
| Daiichi Sankyo INC. | $70.16 | 2024-2025 | Enhertu |
| Celgene Corporation | $67.10 | 2024-2025 | Reblozyl |
| Cti Biopharma Corp. | $50.07 | 2023 | Vonjo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $44.73 | 2024 | Brukinsa |
| Gilead Sciences, INC. | $44.64 | 2021-2024 | |
| Tempus Ai, INC | $42.45 | 2024 | |
| Genzyme Corporation | $35.22 | 2022 | |
| Incyte Corporation | $24.51 | 2024 | Jakafi |
| Glaxosmithkline, LLC. | $22.60 | 2025 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $22.50 | 2023 | Fotivda |
| Emd Serono, INC. | $21.91 | 2024 | |
| Mirati Therapeutics, INC. | $17.33 | 2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2021 | |
| Boston Scientific Corporation | $12.92 | 2021 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Exelixis INC. | $11.91 | 2021 | |
| Clovis Oncology, INC. | $5.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Gurtler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.